Recent research in our laboratory has centered on studies of polyacrylate and polyacrylamide nanoparticle emulsions for use in antibiotic delivery. Our goal is to develop these nanoparticle emulsions for treatment of life-threatening bacterial infections such as those caused by methicillinresistant Staphylococcus aureus (MRSA). For this intended application, it is necessary to ensure that the biological activity of the emulsion is due only to the drug attached to the polymeric chain, rather than to any extraneous components. To investigate this, we evaluated cytotoxicity and microbiological activity of the nanoparticle emulsions before and after purification by centrifugation, dialysis, and gel filtration. Depending on the amount of surfactant used, all or most of the microbial and cellular toxicity can be removed by a simple purification procedure.

Recent efforts in our laboratory have explored the use of polyacrylate nanoparticles in aqueous media as stable emulsions for potential applications in treating drug-resistant bacterial infections. These emulsions are made by emulsion polymerization of acrylated antibiotic compounds in a mixture of butyl acrylate and styrene (7:3 w:w) using sodium dodecyl sulfate (SDS) as a surfactant. Prior work in our group established that the emulsions required purification to remove toxicity associated with extraneous surfactant present in the media. This paper summarizes our investigations of poly(butyl acrylate-styrene) emulsions made using anionic, cationic, zwitterionic, and non-charged (amphiphilic) surfactants, as well as attachable surfactant monomers (surfmers), comparing the cytotoxicity and microbiological activity levels of the emulsion both before and after purification. Conflict of Interest Statement:Edward Turos is co-inventor on a US patent application by the University of South Florida for the polyacrylate nanoparticle antibiotics, the subject of this publication. Dr. Turos is also co-founder, chief scientific advisor, and shareholder of Nanopharma Technologies, Inc., a University of South Florida spin-out company. Nanopharma Technologies, Inc., has licensed the nanoparticles technology from University of South Florida for potential commercial development.Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access Author ManuscriptNanomedicine. Author manuscript; available in PMC 2010 December 1. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author ManuscriptOur results show that the attachment of a polymerizable surfmer onto the matrix of the nanoparticle neither improves nor diminishes cytotoxic or antibacterial effects of the emulsion, regardless of whether the emulsions are purified or not, and that the optimal properties are associated with the use of the non-ionic surfactants versus those carrying anionic, cationic, or zwitterionic charge. Incorporation of an N-thiolated β-lactam antibacterial agent onto the nanoparticle matrix via covalent attachment endows the emulsion with antibiotic properties against pathogenic bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), without changing the physical properties of the nanoparticles or their emulsions.

No abstract

No abstract